RE:RE:RE:Biotech M&A is picking back up according to BiopharmaDiveBaral: I think we’re seeing what we expected to see.
We said divest-to-invest will continue to be a theme. We said in our prior report that it [an M&A comeback] was a matter of time, because the industry fundamentals continue to be strong.
We said the therapeutic areas where the larger unmet need will continue to be in areas such as oncology, such as immunology; that has continued to happen.
And we said the good companies with what I’ll call quality assets will continue to attract higher valuations, so that hasn’t really changed from our perspective.
So we’re glad that what we have narrated as a forward looking comment continues to unfold as we look at the last two quarters in 2023, and we expect the same for the back half.